NCT01433458View on ClinicalTrials.gov

Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Hepatic Impairment
Interventions
DRUG

RLX030A

RLX030 is administered as a continuous 24 hour infusion

Trial Locations (2)

115419

Novartis Investigative Site, Moscow

D-67269

Novartis Investigative Site, Grünstadt

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY